CD7在非M3急性髓系白血病中表达及其意义

Expression level of CD7 in non-M3 acute myeloid leukemia and its prognostic significance

目的探讨CD7在非M3急性髓系白血病患者中的表达及其对患者预后的意义。方法选取2011—2015年收治的198例原发性非M3急性髓系白血病患者,应用流式细胞术检测骨髓样本中白血病细胞中CD7的表达,根据结果将患者分为CD7^+组与CD7^-组。回顾性分析两组患者的临床与实验室检查特点及生存状况等资料。结果 CD7在非M3急性髓系白血病患者中的表达比例为34.8%;CD7^+组发病年龄(49岁)高于CD7^-组(44岁)、白细胞数(29.5×10~9个/L)高于CD7^-组(11.7×10~9个/L)、遗传学危险度分层差于CD7^-组,差异均有统计学意义(P<0.05);但两组诱导缓解率、3年无复发存活率、5年总存活率比较,差异均无统计学意义(P>0.05);移植可明显改善两组患者预后。结论 CD7与非M3急性髓系白血病部分高危因素相关,但不能作为独立预后因素。

Objective To investigate the expression level of CD7 in patients with non-M3 acute myeloid leukemia（ AML） and its effect on the prognosis. Methods The expression of CD7 in bone marrow samples was detected by flow cytometry from 198 patients with primary AML（excluding M3） from 2011 to 2015. The patients were divided into CD7^＋ group and CD7^- group,and the clinical laboratorial characteristics and survival status of the two cohorts were analyzed retrospectively. Results The ratio of CD7 expression in non-M3 AML was 34. 8%. CD7^＋ patients had an elder age of onset（ 49 versus 44 years） and higher leukocyte count（ 29. 5 versus 11. 7 ×10^9/L） and poorer risk status than CD7^- patients,the difference had statistical significance（ P〈0. 05）. There was no statistically significant difference in 3-year relapse-free survival and 5-year overall survival（ P〉 0. 05）. Transplantation can significantly improve the survival of both groups of patients. Conclusion CD7 is associated with some risk factors while can not be used as an independent prognostic factor for non-M3 AML patients.